Year-end Reflects 37% Gross Profit Increase and Higher Gross Margins in Line With Refocus of Strategy Aimed at Higher Profit Retail Activities

CHANGCHUN, China and LOS ANGELES, April 6 /PRNewswire-Asia/ -- China Yongxin Pharmaceuticals, Inc. (OTC Bulletin Board: CYXN) (the "Company" or "China Yongxin"), a fast-growing vertically-integrated health products company in China, announced today its financial results for the fourth quarter and for the year ended December 31, 2009.

Net income increased to $5.1 million in 2009, a 26% increase over $4.1 million in 2008. The increase was primarily related to higher margin sales and was largely due to an increase in gross profit resulting from a change in the composition of products sold, specifically, an increase in retail product sales.

Revenues for the year ended 2009 decreased to $47.6 million, or 19.5% from $59.1 million for 2008. The decrease in total revenue was due to the transition of the Company's sales strategy, which, because of the uncertain direction of the National Medical Policy, had been refocused from the wholesale business to the retail and medical facilities sector. Although a broader product portfolio and expanded marketing activities increased 2009 revenues from the Company's retail drug stores by approximately 27.9% over the prior year, it was not sufficient to completely offset a decrease in revenue from the Company's wholesale business, resulting in comparably lower total net revenue. The substantial increase in revenue from the retail segment was attributable to the addition of seven new retail drugstores in 2009, all located in prime locations in the center of cities in Jilin province. To further its new retail oriented sales strategy, the Company recently announced its plan to open 28 new retail stores in 2010.

The Company also reported that basic and diluted earnings per share increased to $0.15 for the year ended December 31, 2009 compared to $0.13 for 2008, based on 35.1 million and 31.2 million diluted weighted average shares outstanding for 2009 and 2008, respectively, and 33.2 million and 31.2 million basic weighted averages shares outstanding for 2009 and 2008, respectively. These shares do not include approximately 1.67 million shares of preferred stock owned by management, which is convertible into 10 million shares of common stock.

The cost of goods sold for the year was $31.3 million, a significant reduction compared to $47.2 million in the prior year. The decrease corresponded with a decrease in sales volume. However, the Company was able to reduce the cost of sales to net sales percentage from approximately 80% in 2008 to 66% in 2009 due to a change in product mix in which the proportion of products sold with higher profit margins increased, such as cosmetics and certain health and nutritional products. The Company improved its gross profit margin by approximately 37.2% from $11.9 million in 2008 to $16.3 million in 2009. The increase in gross margins was primarily due to higher margin retail and medical facilities sales.

Operating expenses for 2009 were $7.1 million, compared to $6.0 million in 2008. Selling expenses remained at approximately the same level, at $3.5 million. Management believes that in 2009 the Company prudently managed utilities usage, transportation costs and sales people to effectively reduce selling expenses and maintain its gross profit. General and administrative expenses for 2009 increased approximately 43.0% to $3.6 million, compared to $2.5 million in 2008. The majority of the increase was related to litigation which was recently concluded.

Income from operations for 2009 was approximately $9.2 million, an increase from the $5.9 million for 2008. Operating margins were 18% and 9.8% for 2009 and 2008, respectively. A substantial portion of the increase resulted from the expansion of the hospital market business and the increase of the sale of the health care, cosmetic and nutrition products as well as medical facilities sales.

Mr. Yongxin Liu, Chairman and Chief Executive Officer of the Company, commented, "During 2007, the Company anticipated potential impact on its wholesale distribution business resulting from uncertainty created by the proposed National Medical Policy. We were pleased that the Chinese government's August 18th issuance of China's Essential Drug List (the "EDL") included over 300 commonly used pharmaceuticals that will be subsidized by the government to provide easier access to all citizens. The Company is a retailer or distributor of 295 of the products on the EDL. We continue to be encouraged by the government's successful effort toward healthcare reform and efforts to boost domestic spending."

Mr. Liu also added, "Our income growth in 2009 indicates that our business model has placed the Company in a strong position to take positive advantage of increased government support of health care and the continued expansion of the economy in China." On March 9 2009, China Yongxin once again demonstrated its "state-of-the-art" approach to providing retail drug customers with a high level of service by formally launching its proprietary Electronic Diagnosis System (the "System"), of which 20 Systems have been installed so far in chain drugstores located in Changchun, Jilin. This proprietary system enables our customers to remotely receive medical diagnosis and conveniently purchase prescription drugs at that store. The Company continues to improve the level of service it offers and leverage its large and growing base of customers who opt in as drugstore "members" and who are then entitled to discounts, rebates and special offers. This strategy, in addition to selling a broader array of higher margin health, beauty and cosmetic products has increased customer retention and improved revenue and profitability in this business segment.

Since the beginning of 2009, China Yongxin has signed 12 exclusive distribution agreements for high margin pharmaceutical products within Jilin province with several well-known pharmaceutical manufacturers including Tianjin Smith Kline and French Laboratories Ltd. As of June 30, 2009, China Yongxin has approximately 216 drugs with exclusive distribution rights in Jilin province. This portfolio is a key component of its long-term growth strategy to leverage the large distribution center and channels established to drive incremental future revenue growth. These agreements are typically one year in duration and are renewable.

                               (TABLE TO FOLLOW)



                      China Yongxin Pharmaceuticals, Inc.
    Consolidated Statements of Income for the Years Ended December 31, 2009
                                    and 2008

                                                     2009            2008
    Net Revenues                              $   47,589,280 $    59,116,534
    Cost of Goods Sold                           (31,271,463)    (47,226,275)
    Gross profit                                  16,317,817      11,890,259
    Operating Expenses:
    Selling expenses                               3,543,383       3,521,147
    General and administrative expenses            3,575,059       2,500,366
     Total operating expenses                      7,118,442       6,021,513
    Income From Operations                         9,199,376       5,868,745
    Other Income (Expense):
    Other income                                     278,846         690,516
    Other expense                                   (137,849)       (152,469)
    Interest income (expense)                          9,173          (6,679)
    Total other income                               150,170         531,368
    Operating Income Before Income Tax and
     Non controlling Interest                      9,349,545       6,400,113

    Provision for income tax                      (2,594,483)     (1,009,643)

    Net Income Before Non controlling
     Interest and Discontinued operations          6,755,062       5,390,470

    Loss from discontinued operations                (30,951)        (84,850)

    Net Income Before Non controlling
     Interest                                      6,724,111       5,305,619

    Non controlling interest                      (1,599,122)     (1,239,480)
    Net Income                                     5,124,989       4,066,139
    Other Comprehensive Item:
    Foreign exchange translation gain                123,209         824,961

    Net Comprehensive Income                  $    5,248,198 $     4,891,100
    Earnings per share
    Basic                                     $         0.15 $          0.13
    Diluted                                   $         0.15 $          0.13
    Weighted average number of shares
     outstanding
    Basic                                         33,240,797      31,150,819
    Diluted                                       35,070,051      31,150,819

About China Yongxin Pharmaceuticals, Inc.

Founded in 1993, China Yongxin Pharmaceutical, Inc. is a vertically-integrated retailer and distributor of Chinese traditional medicines, pharmaceutical preparations, natural health products, health food, cosmetics, and medical equipment in northeastern China. Its retail operations began in 2004, and in 2005, it gained franchise rights from one of the world's largest drug chains for China's Jilin province. The Company had become one of the fastest growing drug retailers in China through its retail chain of 93 drug outlets as well as wholesale distribution in northeastern China. For more information about China Yongxin Pharmaceuticals Inc., please visit http://www.yongxinchina.com .

Forward Looking Statements

This news release contains certain "forward-looking statements." Forward- looking statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and many of which are beyond the Company's control. The forward-looking statements are also identified through the use of words "believe," enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict" "probable," "potential," "possible," "should," "continue," "project", "expect" and other words of similar meaning. Actual results could differ materially from these forward-looking statements as a result of a number of risk factors detailed in the Company's periodic reports filed with the SEC. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and no assurances can be given that such statements will be achieved. China Yongxin Pharmaceuticals Inc. does not assume any duty to publicly update or revise the material contained herein.

    For more information, please contact:

    CORPORATE
     China Yongxin Pharmaceuticals Inc.
     Sam Liu, COO
     Tel:   +1-626-581-9098
     Email: info@yongxinchina.com

    INVESTOR RELATIONS
     Strategic Growth International, Inc.
     Richard Cooper / Linda Ni
     Tel:   +1-212-838-1444
     Email: rcooper@sgi-ir.com; lni@sgi-ir.com

SOURCE China Yongxin Pharmaceuticals, Inc.

Back to top

RELATED LINKS
http://www.yongxinchina.com